kidney cancer renal cell carcinoma
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: •metastatic renal cell cancer with •Intention to start treatment with everolimus •WHO performance score 20 mm Spiral CT scan > 10 mm Non-spiral CT scan > 20 mm •>= 18 years •not pregnant or nursing •women of childbearing potential must use effective contraception •absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial •before patient randomization, written informed consent must be given according to GCP, and local regulations
Exclusion criteria
Exclusion criteria: Are formulated as "no existence of"in inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is change in 89Zr-bevacizumab uptake in tumor lesions between the baseline scan and the scan during treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, after 3 months of treatment. Progression is defined as the appearance of new disease or an increase of 20% in the sum of the longest diameters of the target lesions. | — |
Countries
Netherlands
Outcome results
None listed